Sciencast Management LP bought a new stake in Catalent Inc (NYSE:CTLT) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 20,425 shares of the company’s stock, valued at approximately $813,000.
Other institutional investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Catalent by 29.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,976,203 shares of the company’s stock valued at $363,316,000 after acquiring an additional 1,819,020 shares during the period. Dimensional Fund Advisors LP lifted its stake in Catalent by 1.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,270,970 shares of the company’s stock valued at $57,891,000 after buying an additional 15,686 shares in the last quarter. Hsbc Holdings PLC lifted its stake in Catalent by 11.6% in the 3rd quarter. Hsbc Holdings PLC now owns 24,198 shares of the company’s stock valued at $1,101,000 after buying an additional 2,523 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Catalent in the 3rd quarter valued at approximately $427,000. Finally, Deutsche Bank AG lifted its stake in Catalent by 7.7% in the 3rd quarter. Deutsche Bank AG now owns 426,540 shares of the company’s stock valued at $19,425,000 after buying an additional 30,462 shares in the last quarter. 99.82% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have weighed in on the company. ValuEngine lowered Catalent from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research raised Catalent from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Wednesday, February 6th. First Analysis reissued an “outperform” rating and set a $49.00 price target on shares of Catalent in a research note on Tuesday, March 5th. TheStreet raised Catalent from a “c” rating to a “b-” rating in a research note on Wednesday, February 6th. Finally, UBS Group raised Catalent from a “neutral” rating to a “buy” rating and increased their price target for the stock from $43.00 to $54.00 in a research note on Tuesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $48.83.
Shares of Catalent stock opened at $44.41 on Tuesday. Catalent Inc has a fifty-two week low of $29.23 and a fifty-two week high of $46.43. The firm has a market cap of $5.72 billion, a price-to-earnings ratio of 27.93, a price-to-earnings-growth ratio of 2.15 and a beta of 1.69. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.63 and a current ratio of 2.08.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, February 5th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.08. The company had revenue of $623.00 million for the quarter, compared to analyst estimates of $608.38 million. Catalent had a return on equity of 17.42% and a net margin of 5.48%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.45 EPS. Analysts expect that Catalent Inc will post 1.69 earnings per share for the current fiscal year.
In other news, SVP Lance Miyamoto sold 43,619 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $42.49, for a total transaction of $1,853,371.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Aristippos Gennadios sold 3,392 shares of the company’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $42.18, for a total value of $143,074.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,326 shares of company stock valued at $2,303,676. Insiders own 1.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Sciencast Management LP Invests $813,000 in Catalent Inc (CTLT)” was originally posted by Macon Daily and is owned by of Macon Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://macondaily.com/2019/04/16/sciencast-management-lp-invests-813000-in-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: What is intrinsic value?
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.